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ABSTRACT
Objective: To predict long-term disability outcomes in TEMSO core (NCT00134563) and exten-
sion (NCT00803049) studies in patients with relapsing forms of MS treated with teriflunomide.
Methods: A post hoc analysis was conducted in a subgroup of patients who received teriflunomide
in the core study, had MRI and clinical relapse assessments at months 12 (n 5 552) and 18, and
entered the extension. Patients were allocated risk scores for disability worsening (DW) after 1
year of teriflunomide treatment: 05 low risk; 15 intermediate risk; and 2–35 high risk, based on
the occurrence of relapses (0 to $2) and/or active (new and enlarging) T2-weighted (T2w) lesions
(#3 or .3) after the 1-year MRI. Patients in the intermediate-risk group were reclassified as
responders or nonresponders (low or high risk) according to relapses and T2w lesions on the
18-month MRI. Long-term risk (7 years) of DW was assessed by Kaplan-Meier survival curves.
Results: In patients with a score of 2–3, the risk of 12-week–confirmed DW over 7 years was
significantly higher vs those with a score of 0 (hazard ratio [HR] 5 1.96, p 5 0.0044). Patients
reclassified as high risk at month 18 (18.6%) had a significantly higher risk of DW vs those in the
low-risk group (81.4%; HR 5 1.92; p 5 0.0004).
Conclusions: Over 80% of patients receiving teriflunomide were classified as low risk (respond-
ers) and had a significantly lower risk of DW than those at increased risk (nonresponders) over 7
years of follow-up in TEMSO. Close monitoring of relapses and active T2w lesions after short-
term teriflunomide treatment predicts a differential rate of subsequent DW long term.
ClinicalTrials.gov identifier: TEMSO, NCT00134563; TEMSO extension, NCT00803049. Neurol
Neuroimmunol Neuroinflamm 2017;4:e379; doi: 10.1212/NXI.0000000000000379
GLOSSARY
DW 5 disability worsening; EDSS 5 Expanded Disability Status Scale; HR 5 hazard ratio; IFNb 5 interferon beta; T2w 5 T2
weighted.
Reliable predictors of treatment response would facilitate earlier identification of patients with MS
that is unresponsive to their existing therapy.1–3 Various clinical and MRI parameters have been
used to classify patients according to their response to treatment. The prognostic value of the Rio
score, based on outcomes after 1 year of therapy, was demonstrated in patients treated with
interferon beta (IFNb)4 or glatiramer acetate.5 A simplified version, the modified Rio score, used
a score (0–3) based on the number of new T2-weighted (T2w) lesions (#5 or .5) and clinical
relapses (0, 1, or 2) occurring after 1 year of therapy.6 Patients treated with IFNb who had higher
modified Rio scores after 1 year showed increased risk of disability worsening (DW) over 4–5
years.6,7 A recent analysis of patients treated with IFNb, performed within the MAGNIMS
network, re-evaluated the modified Rio score using a large, multicenter, real-world data set
from more than 1,200 patients8 and redefined the cutoffs for minimal MRI activity as $3
new T2w lesions on the MRI performed after 1 year from treatment start. The present study
From the Biostatistics Unit (M.P.S.), University of Genoa, Italy; Sanofi Genzyme (P.T., P.R.), Chilly-Mazarin, France; Sanofi Genzyme (K.T.),
Cambridge, MA; Fishawack Communications Ltd (C.S.), Abingdon, Oxfordshire, UK; and Department of Medicine, Surgery, and Neurosciences
(N.D.S.), University of Siena, Italy.
Funding information and disclosures are provided at the end of the article. Go to Neurology.org/nn for full disclosure forms. The Article Processing
Charge was funded by the Genzyme.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC
BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used
commercially without permission from the journal.
Neurology.org/nn Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. 1
evaluated whether this revised scoring system,
which was developed for IFNb and evaluated
over the short term,8 was able to predict dis-
ability outcomes for up to 7 years in patients
treated with teriflunomide, a once-daily oral
immunomodulator approved for the treat-
ment of relapsing-remitting MS (AUBAGIO;
Sanofi Genzyme, Cambridge, MA), using
data from the TEMSO extension study
(NCT00803049).
METHODS Study population and design. TEMSO was
a multinational, multicenter, randomized, placebo-controlled,
double-blind, parallel-group phase 3 study in patients with
relapsing forms of MS.9 In the core study (NCT00134563),
1,088 patients were randomized 1:1:1 to receive once-daily oral
placebo (n 5 363), or teriflunomide 7 mg (n 5 366), or 14 mg
(n 5 359), for 108 weeks.
Key inclusion criteria allowed for enrollment of patients aged
18–55 years who met the McDonald 200110 criteria for relapsing-
remitting MS with or without progression, had an Expanded
Disability Status Scale (EDSS) score of#5.5, and had$2 clinical
relapses in the previous 2 years or 1 relapse during the preceding
year. EDSS scores were determined at screening, baseline visit,
and every 12 weeks thereafter, and at unscheduled visits when
patients returned to the clinic for the assessment of potential
relapse. MRIs were taken at baseline and at weeks 24, 48, 72,
and 108. The primary end point was the annualized relapse rate,
and the key secondary end point was 12-week–confirmed DW.
Patients completing the core study were eligible to enter the
long-term extension; those already receiving teriflunomide re-
mained on their original dose, whereas those previously receiving
placebo were randomized 1:1 to teriflunomide 7 or 14 mg and
were treated for up to 9 years.11
Patients were included in this post hoc analysis if they
received either dose of teriflunomide in the core study, had
MRI assessments at 1 year, could be assessed for clinical relapses
at year 1, and entered the extension. Data are presented for the
combined teriflunomide 7- and 14-mg groups (n 5 552).
Standard protocol approvals, registrations, and patient
consents. TEMSO was conducted in accordance with the Inter-
national Conference on Harmonisation Guidelines for Good
Clinical Practice and the Declaration of Helsinki. The protocol
was approved by central and local ethics committees. Patients
provided written informed consent before the commencement
of TEMSO and, again, before entry into the extension. Clinical
Trial (clinicaltrials.gov) identifiers: TEMSO, NCT00134563;
TEMSO extension, NCT00803049.
Defining scoring categories. The MAGNIMS score is
a recently published scoring system8 that classified patients after
1 year of treatment with IFNb for the risk of disease progression
according to the occurrence of relapse (0 to $2) and new and
enlarging T2w lesions (,3 or $3) on 12-month MRIs. In the
TEMSO study, MRIs were performed more frequently (every 6
months), which allowed us to increase the T2w-lesion cutoff to
#3 or.3, according to the observation that 6-monthly scanning
would detect ;30% more lesions than 12-monthly scanning.7
The scoring assessment is reported in figure 1. Patients with
a score of 0, 1, or 2–3 were categorized as having a low, inter-
mediate, or high risk of poor treatment response, respectively.
Patients with a score of 0 were classified as “treatment res-
ponders,” whereas patients with scores of 2 or 3 were classified as
“nonresponders.” In addition, patients initially considered to be
of intermediate risk of disease progression (score 1) were re-
classified 6 months later (month 18 from treatment start) as
responders or nonresponders, based on the algorithm originally
used to monitor response to IFNb.1
In addition, the long-term prognostic value of the use of the
composite end point of patients with no relapse and no MRI activ-
ity (based on active T2w lesions), a concept similar to NEDA (No
Evidence of Disease Activity), during the first year of treatment
with teriflunomide was compared with that of patients with no re-
lapses but minimal MRI activity (i.e., 1, 2, or 3 active T2w lesions).
Statistical analysis. Based on Kaplan-Meier survival curves, the
risk of DW confirmed for 12 weeks was assessed in patients with
valid scores that were classified by a score category or as
responders/nonresponders. Between-group comparisons were made
using a log-rank test with EDSS strata at baseline and region as
stratification variables, and risk reductions were estimated from
Figure 1 Scoring assessment
T2w 5 T2-weighted.
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a proportional hazards model. Figures with Kaplan-Meier curves
are presented until the end of year 7, after which a few patients
(,10%) remained at risk of progression within each group
presented.
RESULTS Of the 723 patients treated with terifluno-
mide 7 or 14 mg in the core TEMSO study, 551
(76.2%) had a computable score at year 1. Of these,
469 patients were treated in the extension and 299
completed 7 years of follow-up (figure 2).
Baseline demographics and clinical disease charac-
teristics are shown in table. Patient characteristics
were consistent with those of the teriflunomide-
treated patients in the overall TEMSO population.
Kaplan-Meier estimates of the proportion of pa-
tients with DW at the end of year 7, categorized by
scoring classification, are shown in figure 3A. The
probability of disability progression was similar in
the score 0 and score 1 categories over the initial years
of the study, followed by a separation of the curves
around 3 years. Over a period of 7 years of follow-up
in the TEMSO extension, the probability of 12-week–
confirmed DW was significantly increased in the high-
risk categories (scores 2 or 3) compared with those in
the low-risk categories (score 0) (hazard ratio [HR],
1.96; p5 0.0044), as well as in the high-risk categories
compared with the combined low-risk/intermediate-
risk score category (HR, 1.68; p 5 0.0157).
In addition, when patients with an intermediate
score of 1 were recategorized after an additional 6
months of follow-up, those classified as nonrespond-
ers had a significantly higher rate of DW over 7 years
compared with those classified as responders (HR,
1.92; p 5 0.0004; figure 3B).
Outcomes remained consistent for the group of pa-
tients treated with teriflunomide 14 mg only, although
because of the small sample size, the differences
between groups were not significant (data not shown).
The distribution of patients by scoring category at
the end of year 1 is shown in figure 4A. Most patients
(;90%) were categorized as having low or interme-
diate risk of disease progression. Patients with an ini-
tial score of 1 (intermediate risk) after 1 year of
treatment included those with no relapses and .3
active T2w lesions or those with 1 relapse and #3
active T2w lesions. These patients were reclassified 6
months later as responders (no relapses and ,2 new
T2w lesions) or nonresponders ($1 relapse or $2
new T2w lesions). The majority of these patients
(;80%) were reclassified as responders (figure 4B).
The responder vs nonresponder classification had
a positive predictive value of 67% and a negative pre-
dictive value of 45%, a sensitivity of 84%, a specificity
of 24%, and a global accuracy of 63%.
Finally, because the absence of any disease activity,
the so-called No Evidence of Disease Activity status,
Figure 2 Patient disposition
Table Baseline demographics and disease characteristics
Characteristic
Teriflunomide-treated
patients with computable
risk score (n 5 551)
Teriflunomide-treated
patients in the overall
TEMSO population (n 5 723)
Age, y, mean (SD) 37.7 (8.6) 37.6 (8.6)
Female, n (%) 386 (70.1) 508 (70.8)
No. of relapses 1 year before randomization, mean (SD) 1.3 (0.7) 1.3 (0.7)
Years since first symptoms of MS, mean (SD) 8.78 (6.87) 8.74 (6.78)
MS subtype, n (%)
Relapsing-remitting 511 (92.7) 664 (91.8)
Secondary progressive 20 (3.6) 29 (4.0)
Progressive relapsing 20 (3.6) 30 (4.1)
EDSS score, mean (SD) 2.60 (1.27) 2.68 (1.29)
EDSS score, median (min:max) 2.5 (0.0:5.5) 2.5 (0.0:6.0)
Abbreviation: EDSS 5 Expanded Disability Status Scale.
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is the emerging target of newer therapies,12,13 we
examined whether the proposed cutoff of 3 active
T2w lesions might be too conservative for defining
responders among teriflunomide-treated patients.
This analysis showed no significant difference
between patients without any relapse or MRI activity,
and those with no relapses and minimal MRI activity
(i.e., 1, 2, or 3 active T2w lesions), with respect to the
risk of experiencing DW over the subsequent 7 years
(figure 5).
DISCUSSION Reliable predictors of treatment out-
comes in MS would help to identify patients who
may continue to have disease activity while receiving
treatment and who may therefore benefit from
a change in therapy. Earlier stage treatment decisions,
when alternative agents are expected to be more effec-
tive, are likely to improve longer-term outcomes in
these patients.
This is the first report of predictive scoring analysis
applied to patients with relapsing forms of MS treated
with teriflunomide. Consistent with earlier reports
of patients treated with IFNb,4,14–16 glatiramer
acetate,5,14 and fingolimod,17 clinical relapses and dis-
ease activity on MRI during the early stages of treat-
ment were predictive of a subsequent differential rate
of DW. A small number of active T2w lesions (#3) in
the absence of relapses had less predictive value, sug-
gesting that a small amount of MRI activity can be
tolerated, and a minimal amount of MRI activity
alone should not be a criterion for switching
treatments.
Teriflunomide-treated patients from the TEMSO
study who were characterized as having low risk of
disease progression after 1 year of treatment demon-
strated significantly lower probability of DW over 7
years of follow-up (median follow-up time was 292
weeks), when compared with patients who were clas-
sified as having high risk. Approximately, 26% of pa-
tients were classified as having intermediate risk after
1 year; these patients may be more difficult to assess
in terms of response to therapy and subsequent treat-
ment choices. An additional evaluation of relapses
and disease activity on MRI, as applied in previous
analyses at 1.5 years,7,18 allowed these patients to be
reclassified as responders or nonresponders, with
Figure 3 Probability of disability worsening by scoring classification
(A) At the end of year 1 and (B) on reclassification of patients with intermediate score 1, 6 months later. *Nonresponders vs responders. HR 5 hazard ratio.
Figure 4 Distribution of patients by scoring classification
(A) At the end of year 1 and (B) on reclassification of patients with score 1, 6 months later.
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a greater proportion of TEMSO patients (.81%)
being classified as responders.
In our analysis, the predictive value of the scoring
classification, particularly in the intermediate group,
extended to over 7 years in the TEMSO long-term
extension, which extends the finding of studies based
on a shorter follow-up. A limitation of this analysis is
the loss of patients to follow-up in the extension,
although our results support the use of teriflunomide
for the long-term treatment of most patients with
relapsing forms of MS. It could also be suggested that
MRI outcomes of patients at 1 year might be better
compared with outcomes after steady-state levels of
teriflunomide were achieved (for example, after 6
months), rather than at baseline. However, to allow
for comparisons with other analyses, we followed an
approach consistent with validated methodology.4,7,18
This may also better represent the real-world setting,
where MRI assessments may be performed less fre-
quently than in clinical trials. Approximately 90% of
patients receiving teriflunomide in the TEMSO study
were characterized as having low or intermediate risk of
subsequent disease progression. Long-term observation
is important in studies of response to treatment and is
of particular significance in patients withMS who dem-
onstrate heterogeneous responses to therapy over time.
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